Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria: * Women or men aged \>/=18 years * Patients with a measurable histologically confirmed Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Small Lymphocytic Lymphoma (SLL) and Marginal Zone Lymphoma (MZL) (Arm A), or patients with an evaluable immunophenotypically confirmed CLL (Arm B), or patients with a measurable Multiple Myeloma t(11;14) (arm A expansion part) according to International Myeloma Working Group (IMWG) criteria * Relapsed after or refractory disease to standard treatments, and require treatment in the opinion of the investigator * Estimated life expectancy \> 12 weeks * World Health Organization (WHO) performance status 0-2 * Adequate bone marrow, renal and hepatic functions * No evidence or treatment for another malignancy within 2 years prior to study entry. Curatively treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia is allowed Additional inclusion criteria for food interaction cohort: * B-cell NHL patients at low risk of tumour lysis syndrome (TLS) * Recent/concomitant treatment altering gastric pH Exclusion Criteria: * Previous treatment with a BH3 mimetic * Previous therapy for the studied disease within 3 weeks before first intake * Radioimmunotherapy, radiotherapy within 8 weeks before first intake * Major surgery within 3 weeks before first day of study drug dosing * Corticosteroids \>= 20 mg prednisone equivalent per day within 7 days before first intake * Anticoagulant oral drugs, aspirin \> 325 mg/day within 7 days prior to first S 55746 intake * Positive direct antiglobulin test (Coombs test) and haptoglobin below normal value * Prior allogenic stem cell transplant * Autologous stem cell transplant within 3 months before first intake * NHL patients diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukaemia * Human immunodeficiency virus (HIV) * Known acute or chronic hepatitis B or hepatitis C * Impaired cardiac function * Medications known to prolong corrected QT (QTc) interval * History or/ clinically suspicious for cancer- related Central Nervous System disease * Solitary extramedullary plasmacytoma * Laboratory Signs of TLS * Strong or moderate CYP3A4 inhibitors/inducers (treatment, food or drink products) * Treatment highly metabolized by the CYP3A4 or CYP2D6 and/or substrates with a narrow therapeutic index, multienzyme and/or OATP and/or P-gp substrates or herbal products. * Known hypersensitivity to rasburicase * Glucose-6-phosphate dehydrogenase (G6PD) deficiency and other cellular metabolic disorders known to cause haemolytic anaemia * Patients receiving proton pump inhibitor